Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.
about
Exercise interventions for men with prostate cancerExercise interventions for men with prostate cancerLifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an updateLow rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapyRisk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Effects of resistance exercise in prostate cancer patients: a meta-analysis.Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis.Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?Managing bone metastases and reducing skeletal related events in prostate cancer.Adverse effects of androgen-deprivation therapy in prostate cancer and their management.Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy.Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trialTreatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
P2860
Q24187552-706C4EB9-8D25-4686-8B57-E783F69C83E7Q24194544-EA8CB4E5-63EB-49A2-96A3-A83FF38C2B61Q33900049-2C3E8178-F238-43DB-83CF-17482CF10BF2Q35206815-1930D2BC-73E0-45F3-9EC9-D59CFCFEFF13Q35829609-F4501380-228A-4020-B7BE-F07CA8969FF9Q36187103-B03D495A-8903-4CC9-8208-627FE2323FD4Q36397349-09739D66-DBC2-466F-9413-A69B5FAE8910Q37430019-7BE7D690-2948-4ACE-9828-CF4813B0D916Q38195921-8A38A75A-41CF-4A4D-995F-09401FCEEFA4Q38211359-A54EAC82-20AD-4000-9585-B9BF06E687C8Q38261253-43D74B5F-C297-4DBB-8A61-B4AC3F647475Q41451263-B94AE5D9-AF81-49D9-AEDF-AC9D58D35BCEQ42281198-CAF7E3B6-B6F6-4262-9C2B-88441CB495A3Q47189119-3E0227A3-9D38-4366-9DD5-DB25316D030D
P2860
Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Timing of androgen deprivation ...... e cancer in the United States.
@ast
Timing of androgen deprivation ...... e cancer in the United States.
@en
type
label
Timing of androgen deprivation ...... e cancer in the United States.
@ast
Timing of androgen deprivation ...... e cancer in the United States.
@en
prefLabel
Timing of androgen deprivation ...... e cancer in the United States.
@ast
Timing of androgen deprivation ...... e cancer in the United States.
@en
P2093
P2860
P356
P1476
Timing of androgen deprivation ...... e cancer in the United States.
@en
P2093
Cecilia Yee
Hal Morgenstern
Jennifer L Beebe-Dimmer
John Acquavella
Karynsa Cetin
Kendra L Schwartz
Vahakn Shahinian
P2860
P356
10.1002/PDS.2258
P577
2011-11-24T00:00:00Z